Videos

Ken Shain, MD, PhD, discussed some of the research in multiple myeloma that was featured in a recent FaceOff program, and how these recent advances may change the standard of care.

Before closing out their discussion on the evolving treatment landscape of advanced renal cell carcinoma, Matthew Campbell, MD, MS, and Brian Rini, MD, highlight clinical trials in the adjuvant setting.

Shared insight on the results from triplet therapy–centered clinical trials in advanced renal cell carcinoma and how these might inform treatment strategies as the paradigm continues to evolve.

In a conversation during the 2022 American Society of Hematology Annual Meeting, an expert from the University of Texas MD Anderson Cancer Center, spoke to how treatments have improved for patients with mantle cell lymphoma.

A brief review on how best to identify, delay, or avoid brain metastases in patients diagnosed with metastatic HER2+ breast cancer.

Centering discussion on a patient scenario of stage II HR+ breast cancer, expert panelists consider how they would approach workup and selection of therapy.

Having outlined available treatment options for patients with HER2+ metastatic breast cancer, expert panelists share which factors help to select optimal therapy.

Momelotinib continues to show benefit in reducing splenic symptoms and anemia in myelofibrosis in the second-line setting, making it a likely first treatment choice, according to an expert from the University of Texas MD Anderson Cancer Center.

Heather McArthur, MD, describes what treatment options she would consider in the third-line setting for HER2+ mBC.

Before closing out their review on the management of multiple myeloma, panelists consider disparities in care and share how these barriers are being addressed.

Andrew Brenner, MD, explains when physicians should screen patients with HER2+ breast cancer for brain metastases.

A comprehensive review of novel therapy being investigated in the setting of relapsed/refractory multiple myeloma to expand the bispecific antibody and CAR T-cell therapy armamentarium.

The panel shares some unmet needs in the multiple myeloma treatment landscape and exciting developments on the horizon.

Virginia Kaklamani, MD and Heather McArthur, MD begin by discussing new data regarding the use of aromatase inhibitors and ovarian function suppression in women with HR+ early breast cancer.

Harry P. Erba, MD, PhD, highlights key data on ziftomenib in patients with relapsed/refractory acute myeloid leukemia and its potential as part of a combination regimen.

Melissa Alsina, MD, shares her excitement for an upcoming program wherein she and other key opinion leaders from the Moffit Cancer Center review updated data and optimal treatment strategies in the setting of multiple myeloma.

Alexander Spira, MD, PhD, FACP, of the Virginia Cancer Specialists, discusses how the FDA approval of adagrasib for KRAS G12C–mutated non–small cell lung cancer can provide benefit for this patient population.

Dr Tanios Bekaii-Saab describes for which patient groups he would use anti-HER2 therapies as a second-line treatment for HER2+ metastatic colorectal cancer.

Expert panelists review data from the MOUNTAINEER study, which tested tucatinib alone or in combination with trastuzumab in patients with metastatic colorectal cancer.

Patient Elle Charnisky shares her experience with a conventional chemotherapy treatment for her HER2+ metastatic colorectal cancer before transitioning to targeted therapies.

Shared perspective on the use of trastuzumab deruxtecan in HER2+ metastatic colorectal cancer following results from the DESTINY-CRC01 trial.

Experts from the Cleveland Clinic provide an overview of recent updates in the treatment landscape for patients with multiple myeloma, discussing patient cases, clinical trials, and improving outcomes for patients.

Experts Matthew Campbell, MD, MS, and Brian Rini, MD, provide a brief review of recent clinical data in the setting of relapsed/refractory renal cell carcinoma.

A broad look at the data from several recent first-line clinical trials in the setting of advanced renal cell carcinoma and considerations for how they may impact real-world practice.

Robert Mutter, MD, of Mayo Clinic says that proton postmastectomy radiation therapy allows for excellent tissue sparing in the management of breast cancer.

Patients with multiple ipsilateral breast cancer might benefit from having a preoperative MRI before proceeding with breast conservation therapy, according to Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota.

Comprehensive insight to the treatment armamentarium for HER2+ metastatic breast cancer throughout several lines of therapy.

Expert panelists open their discussion on HER2+ breast cancer by reviewing a patient case of metastatic disease with no CNS involvement.

Dr Tuchman highlights exciting bispecific agents in investigation for the treatment of relapsed/refractory multiple myeloma.

Joyce O’Shaughnessy, MD, starts a discussion on maintenance therapy with trastuzumab deruxtecan in patient with HER2+ mBC.